Histone deacetylase inhibitors in hepatocellular carcinoma: A therapeutic perspective

Surgical Oncology

Volumn 27, Issue 4, 2018, Pages 611-618

  Tsilimigras, Diamantis I ^a   Ntanasis Stathopoulos, Ioannis ^a   Moris, Demetrios ^b   Spartalis, Eleftherios ^a   Pawlik, Timothy M ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Hepatocellular carcinoma; Histone deacetylases; Targeted therapy

Indexed keywords

HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR;

CANCER THERAPY; CHEMICAL STRUCTURE; COMBINATION CHEMOTHERAPY; EPIGENETICS; FOOD AND DRUG ADMINISTRATION; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MONOTHERAPY; PRIORITY JOURNAL; REVIEW; ANIMAL; HUMAN; LIVER TUMOR; PROGNOSIS;

ANIMALS; CARCINOMA, HEPATOCELLULAR; HISTONE DEACETYLASE INHIBITORS; HUMANS; LIVER NEOPLASMS; PROGNOSIS;

EID: 85053195595     PISSN: 09607404     EISSN: 18793320     Source Type: Journal    
DOI: 10.1016/j.suronc.2018.07.015     Document Type: Review

References (93)

1. Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D., Bray, F., GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. 2013, International Agency for Research on Cancer, Lyon, France Available from: http://globocan.iarc.fr. (Accessed 14 April 2018)
2. World Cancer Research Fund International/American Institute for Cancer Research, Continuous Update Project Report: Diet, Nutrition, Physical Activity and Liver Cancer., 2015 Available at: wcrf.org/sites/default/les/Liver-Cancer-2015-Report.pdf.
3. Grandhi, M.S., Kim, A.K., Ronnekleiv-Kelly, S.M., Kamel, I.R., Ghasebeh, M.A., Pawlik, T.M., Hepatocellular carcinoma: from diagnosis to treatment. Surg Oncol 25:2 (2016), 74–85.
4. Llovet, J.M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.F., de Oliveira, A.C., Santoro, A., Raoul, J.L., Forner, A., Schwartz, M., Porta, C., Zeuzem, S., Bolondi, L., Greten, T.F., Galle, P.R., Seitz, J.F., Borbath, I., Haussinger, D., Giannaris, T., Shan, M., Moscovici, M., Voliotis, D., Bruix, J., Group, S.I.S., Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359:4 (2008), 378–390.
5. Niu, M., Hong, D., Ma, T.C., Chen, X.W., Han, J.H., Sun, J., Xu, K., Short-term and long-term efficacy of 7 targeted therapies for the treatment of advanced hepatocellular carcinoma: a network meta-analysis: efficacy of 7 targeted therapies for AHCC. Medicine (Baltim.), 95(49), 2016 e5591.
6. Gnoni, A., Santini, D., Scartozzi, M., Russo, A., Licchetta, A., Palmieri, V., Lupo, L., Faloppi, L., Palasciano, G., Memeo, V., Angarano, G., Brunetti, O., Guarini, A., Pisconti, S., Lorusso, V., Silvestris, N., Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?. Expert Opin. Ther. Targets 19:12 (2015), 1623–1635.
7. Ntanasis-Stathopoulos, J., Tzanninis, J.G., Philippou, A., Koutsilieris, M., Epigenetic regulation on gene expression induced by physical exercise. J. Musculoskelet. Neuronal Interact. 13:2 (2013), 133–146.
8. Zhang, H., Shang, Y.P., Chen, H.Y., Li, J., Histone deacetylases function as novel potential therapeutic targets for cancer. Hepatol. Res. 47:2 (2017), 149–159.
9. Chen, H.P., Zhao, Y.T., Zhao, T.C., Histone deacetylases and mechanisms of regulation of gene expression. Crit. Rev. Oncog. 20:1–2 (2015), 35–47.
10. Yoon, S., Eom, G.H., HDAC and HDAC inhibitor: from cancer to cardiovascular diseases. Chonnam Med J 52:1 (2016), 1–11.
11. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144:5 (2011), 646–674.
12. Liu, M., Jiang, L., Guan, X.Y., The genetic and epigenetic alterations in human hepatocellular carcinoma: a recent update. Protein Cell 5:9 (2014), 673–691.
13. Nam, S.W., Park, J.Y., Ramasamy, A., Shevade, S., Islam, A., Long, P.M., Park, C.K., Park, S.E., Kim, S.Y., Lee, S.H., Park, W.S., Yoo, N.J., Liu, E.T., Miller, L.D., Lee, J.Y., Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. Hepatology 42:4 (2005), 809–818.
14. Buurman, R., Gurlevik, E., Schaffer, V., Eilers, M., Sandbothe, M., Kreipe, H., Wilkens, L., Schlegelberger, B., Kuhnel, F., Skawran, B., Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells. Gastroenterology 143:3 (2012), 811–820 e15.
15. Xie, H.J., Noh, J.H., Kim, J.K., Jung, K.H., Eun, J.W., Bae, H.J., Kim, M.G., Chang, Y.G., Lee, J.Y., Park, H., Nam, S.W., HDAC1 inactivation induces mitotic defect and caspase-independent autophagic cell death in liver cancer. PLoS One, 7(4), 2012, e34265.
16. Noh, J.H., Jung, K.H., Kim, J.K., Eun, J.W., Bae, H.J., Xie, H.J., Chang, Y.G., Kim, M.G., Park, W.S., Lee, J.Y., Nam, S.W., Aberrant regulation of HDAC2 mediates proliferation of hepatocellular carcinoma cells by deregulating expression of G1/S cell cycle proteins. PLoS One, 6(11), 2011, e28103.
17. Noh, J.H., Bae, H.J., Eun, J.W., Shen, Q., Park, S.J., Kim, H.S., Nam, B., Shin, W.C., Lee, E.K., Lee, K., Jang, J.J., Park, W.S., Lee, J.Y., Nam, S.W., HDAC2 provides a critical support to malignant progression of hepatocellular carcinoma through feedback control of mTORC1 and AKT. Canc. Res. 74:6 (2014), 1728–1738.
18. Wu, L.M., Yang, Z., Zhou, L., Zhang, F., Xie, H.Y., Feng, X.W., Wu, J., Zheng, S.S., Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma. PLoS One, 5(12), 2010 e14460.
19. Wu, J., Du, C., Lv, Z., Ding, C., Cheng, J., Xie, H., Zhou, L., Zheng, S., The up-regulation of histone deacetylase 8 promotes proliferation and inhibits apoptosis in hepatocellular carcinoma. Dig. Dis. Sci. 58:12 (2013), 3545–3553.
20. Datta, J., Kutay, H., Nasser, M.W., Nuovo, G.J., Wang, B., Majumder, S., Liu, C.G., Volinia, S., Croce, C.M., Schmittgen, T.D., Ghoshal, K., Jacob, S.T., Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Canc. Res. 68:13 (2008), 5049–5058.
21. Fan, J., Lou, B., Chen, W., Zhang, J., Lin, S., Lv, F.F., Chen, Y., Down-regulation of HDAC5 inhibits growth of human hepatocellular carcinoma by induction of apoptosis and cell cycle arrest. Tumour Biol 35:11 (2014), 11523–11532.
22. Yuan, J.H., Yang, F., Chen, B.F., Lu, Z., Huo, X.S., Zhou, W.P., Wang, F., Sun, S.H., The histone deacetylase 4/SP1/microrna-200a regulatory network contributes to aberrant histone acetylation in hepatocellular carcinoma. Hepatology 54:6 (2011), 2025–2035.
23. Zheng, Y., Chen, H., Yin, M., Ye, X., Chen, G., Zhou, X., Yin, L., Zhang, C., Ding, B., MiR-376a and histone deacetylation 9 form a regulatory circuitry in hepatocellular carcinoma. Cell. Physiol. Biochem. 35:2 (2015), 729–739.
24. Park, B.L., Kim, Y.J., Cheong, H.S., Lee, S.O., Han, C.S., Yoon, J.H., Park, J.H., Chang, H.S., Park, C.S., Lee, H.S., Shin, H.D., HDAC10 promoter polymorphism associated with development of HCC among chronic HBV patients. Biochem. Biophys. Res. Commun. 363:3 (2007), 776–781.
25. Jung, K.H., Noh, J.H., Kim, J.K., Eun, J.W., Bae, H.J., Chang, Y.G., Kim, M.G., Park, W.S., Lee, J.Y., Lee, S.Y., Chu, I.S., Nam, S.W., Histone deacetylase 6 functions as a tumor suppressor by activating c-Jun NH2-terminal kinase-mediated beclin 1-dependent autophagic cell death in liver cancer. Hepatology 56:2 (2012), 644–657.
26. Bae, H.J., Noh, J.H., Kim, J.K., Eun, J.W., Jung, K.H., Kim, M.G., Chang, Y.G., Shen, Q., Kim, S.J., Park, W.S., Lee, J.Y., Nam, S.W., MicroRNA-29c functions as a tumor suppressor by direct targeting oncogenic SIRT1 in hepatocellular carcinoma. Oncogene 33:20 (2014), 2557–2567.
27. Kim, J.K., Noh, J.H., Jung, K.H., Eun, J.W., Bae, H.J., Kim, M.G., Chang, Y.G., Shen, Q., Park, W.S., Lee, J.Y., Borlak, J., Nam, S.W., Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b. Hepatology 57:3 (2013), 1055–1067.
28. Chen, J., Chan, A.W., To, K.F., Chen, W., Zhang, Z., Ren, J., Song, C., Cheung, Y.S., Lai, P.B., Cheng, S.H., Ng, M.H., Huang, A., Ko, B.C., SIRT2 overexpression in hepatocellular carcinoma mediates epithelial to mesenchymal transition by protein kinase B/glycogen synthase kinase-3beta/beta-catenin signaling. Hepatology 57:6 (2013), 2287–2298.
29. Marquardt, J.U., Fischer, K., Baus, K., Kashyap, A., Ma, S., Krupp, M., Linke, M., Teufel, A., Zechner, U., Strand, D., Thorgeirsson, S.S., Galle, P.R., Strand, S., Sirtuin-6-dependent genetic and epigenetic alterations are associated with poor clinical outcome in hepatocellular carcinoma patients. Hepatology 58:3 (2013), 1054–1064.
30. Ran, L.K., Chen, Y., Zhang, Z.Z., Tao, N.N., Ren, J.H., Zhou, L., Tang, H., Chen, X., Chen, K., Li, W.Y., Huang, A.L., Chen, J., SIRT6 overexpression potentiates apoptosis evasion in hepatocellular carcinoma via BCL2-associated X protein-dependent apoptotic pathway. Clin. Canc. Res. 22:13 (2016), 3372–3382.
31. Quint, K., Agaimy, A., Di Fazio, P., Montalbano, R., Steindorf, C., Jung, R., Hellerbrand, C., Hartmann, A., Sitter, H., Neureiter, D., Ocker, M., Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC. Virchows Arch. 459:2 (2011), 129–139.
32. Ler, S.Y., Leung, C.H., Khin, L.W., Lu, G.D., Salto-Tellez, M., Hartman, M., Iau, P.T., Yap, C.T., Hooi, S.C., HDAC1 and HDAC2 independently predict mortality in hepatocellular carcinoma by a competing risk regression model in a Southeast Asian population. Oncol. Rep. 34:5 (2015), 2238–2250.
33. Jang, K.Y., Noh, S.J., Lehwald, N., Tao, G.Z., Bellovin, D.I., Park, H.S., Moon, W.S., Felsher, D.W., Sylvester, K.G., SIRT1 and c-Myc promote liver tumor cell survival and predict poor survival of human hepatocellular carcinomas. PLoS One, 7(9), 2012, e45119.
34. Zhang, C.Z., Liu, L., Cai, M., Pan, Y., Fu, J., Cao, Y., Yun, J., Low SIRT3 expression correlates with poor differentiation and unfavorable prognosis in primary hepatocellular carcinoma. PLoS One, 7(12), 2012, e51703.
35. Wang, J.X., Yi, Y., Li, Y.W., Cai, X.Y., He, H.W., Ni, X.C., Zhou, J., Cheng, Y.F., Jin, J.J., Fan, J., Qiu, S.J., Down-regulation of sirtuin 3 is associated with poor prognosis in hepatocellular carcinoma after resection. BMC Canc., 14, 2014, 297.
36. Pathil, A., Armeanu, S., Venturelli, S., Mascagni, P., Weiss, T.S., Gregor, M., Lauer, U.M., Bitzer, M., HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. Hepatology 43:3 (2006), 425–434.
37. Yang, W., Zhao, X., Pei, F., Ji, M., Ma, W., Wang, Y., Jiang, G., Activation of the intrinsic apoptosis pathway contributes to the induction of apoptosis in hepatocellular carcinoma cells by valproic acid. Oncol Lett 9:2 (2015), 881–886.
38. Sun, G., Mackey, L.V., Coy, D.H., Yu, C.Y., Sun, L., The histone deacetylase inhibitor vaproic acid induces cell growth arrest in hepatocellular carcinoma cells via suppressing Notch signaling. J. Canc. 6:10 (2015), 996–1004.
39. Armeanu, S., Bitzer, M., Lauer, U.M., Venturelli, S., Pathil, A., Krusch, M., Kaiser, S., Jobst, J., Smirnow, I., Wagner, A., Steinle, A., Salih, H.R., Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Canc. Res. 65:14 (2005), 6321–6329.
40. Zopf, S., Ocker, M., Neureiter, D., Alinger, B., Gahr, S., Neurath, M.F., Di Fazio, P., Inhibition of DNA methyltransferase activity and expression by treatment with the pan-deacetylase inhibitor panobinostat in hepatocellular carcinoma cell lines. BMC Canc., 12, 2012, 386.
41. Di Fazio, P., Montalbano, R., Neureiter, D., Alinger, B., Schmidt, A., Merkel, A.L., Quint, K., Ocker, M., Downregulation of HMGA2 by the pan-deacetylase inhibitor panobinostat is dependent on hsa-let-7b expression in liver cancer cell lines. Exp. Cell Res. 318:15 (2012), 1832–1843.
42. Henrici, A., Montalbano, R., Neureiter, D., Krause, M., Stiewe, T., Slater, E.P., Quint, K., Ocker, M., Di Fazio, P., The pan-deacetylase inhibitor panobinostat suppresses the expression of oncogenic miRNAs in hepatocellular carcinoma cell lines. Mol. Carcinog. 54:8 (2015), 585–597.
43. Di Fazio, P., Schneider-Stock, R., Neureiter, D., Okamoto, K., Wissniowski, T., Gahr, S., Quint, K., Meissnitzer, M., Alinger, B., Montalbano, R., Sass, G., Hohenstein, B., Hahn, E.G., Ocker, M., The pan-deacetylase inhibitor panobinostat inhibits growth of hepatocellular carcinoma models by alternative pathways of apoptosis. Cell. Oncol. 32:4 (2010), 285–300.
44. Montalbano, R., Waldegger, P., Quint, K., Jabari, S., Neureiter, D., Illig, R., Ocker, M., Di Fazio, P., Endoplasmic reticulum stress plays a pivotal role in cell death mediated by the pan-deacetylase inhibitor panobinostat in human hepatocellular cancer cells. Transl Oncol 6:2 (2013), 143–157.
45. Di Fazio, P., Waldegger, P., Jabari, S., Lingelbach, S., Montalbano, R., Ocker, M., Slater, E.P., Bartsch, D.K., Illig, R., Neureiter, D., Wissniowski, T.T., Autophagy-related cell death by pan-histone deacetylase inhibition in liver cancer. Oncotarget 7:20 (2016), 28998–29010.
46. Gahr, S., Mayr, C., Kiesslich, T., Illig, R., Neureiter, D., Alinger, B., Ganslmayer, M., Wissniowski, T., Fazio, P.D., Montalbano, R., Ficker, J.H., Ocker, M., Quint, K., The pan-deacetylase inhibitor panobinostat affects angiogenesis in hepatocellular carcinoma models via modulation of CTGF expression. Int. J. Oncol. 47:3 (2015), 963–970.
47. Song, X., Wang, J., Zheng, T., Song, R., Liang, Y., Bhatta, N., Yin, D., Pan, S., Liu, J., Jiang, H., Liu, L., LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/STAT3/Akt pathway. Mol. Canc., 12(1), 2013, 114.
48. Herold, C., Ganslmayer, M., Ocker, M., Hermann, M., Geerts, A., Hahn, E.G., Schuppan, D., The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J. Hepatol. 36:2 (2002), 233–240.
49. Yamashita, Y., Shimada, M., Harimoto, N., Rikimaru, T., Shirabe, K., Tanaka, S., Sugimachi, K., Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells. Int. J. Canc. 103:5 (2003), 572–576.
50. Svechnikova, I., Ammerpohl, O., Ekstrom, T.J., p21waf1/Cip1 partially mediates apoptosis in hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun. 354:2 (2007), 466–471.
51. Zhang, C.Z., Chen, G.G., Merchant, J.L., Lai, P.B., Interaction between ZBP-89 and p53 mutants and its contribution to effects of HDACi on hepatocellular carcinoma. Cell Cycle 11:2 (2012), 322–334.
52. Carlisi, D., Vassallo, B., Lauricella, M., Emanuele, S., D'Anneo, A., Di Leonardo, E., Di Fazio, P., Vento, R., Tesoriere, G., Histone deacetylase inhibitors induce in human hepatoma HepG2 cells acetylation of p53 and histones in correlation with apoptotic effects. Int. J. Oncol. 32:1 (2008), 177–184.
53. Ganslmayer, M., Konturek, P., Herold, C., Neurath, M.F., Zopf, S., Antitumoral efficacy of four histone deacetylase inhibitors in hepatoma in vitro and in vivo. Anticancer Res. 32:12 (2012), 5263–5269.
54. Schauber, J., Iffland, K., Frisch, S., Kudlich, T., Schmausser, B., Eck, M., Menzel, T., Gostner, A., Luhrs, H., Scheppach, W., Histone-deacetylase inhibitors induce the cathelicidin LL-37 in gastrointestinal cells. Mol. Immunol. 41:9 (2004), 847–854.
55. Kim, S.O., Choi, B.T., Choi, I.W., Cheong, J., Kim, G.Y., Kwon, T.K., Kim, N.D., Choi, Y.H., Anti-invasive activity of histone deacetylase inhibitors via the induction of Egr-1 and the modulation of tight junction-related proteins in human hepatocarcinoma cells. BMB Rep 42:10 (2009), 655–660.
56. Wang, Y.C., Yang, X., Xing, L.H., Kong, W.Z., Effects of SAHA on proliferation and apoptosis of hepatocellular carcinoma cells and hepatitis B virus replication. World J. Gastroenterol. 19:31 (2013), 5159–5164.
57. Liu, Y.L., Yang, P.M., Shun, C.T., Wu, M.S., Weng, J.R., Chen, C.C., Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma. Autophagy 6:8 (2010), 1057–1065.
58. Sato, A., Saito, Y., Sugiyama, K., Sakasegawa, N., Muramatsu, T., Fukuda, S., Yoneya, M., Kimura, M., Ebinuma, H., Hibi, T., Ikeda, M., Kato, N., Saito, H., Suppressive effect of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) on hepatitis C virus replication. J. Cell. Biochem. 114:9 (2013), 1987–1996.
59. Yang, H., Lan, P., Hou, Z., Guan, Y., Zhang, J., Xu, W., Tian, Z., Zhang, C., Histone deacetylase inhibitor SAHA epigenetically regulates miR-17-92 cluster and MCM7 to upregulate MICA expression in hepatoma. Br. J. Canc. 112:1 (2015), 112–121.
60. Hutt, D.M., Roth, D.M., Vignaud, H., Cullin, C., Bouchecareilh, M., The histone deacetylase inhibitor, Vorinostat, represses hypoxia inducible factor 1 alpha expression through translational inhibition. PLoS One, 9(8), 2014 e106224.
61. Chen, M.C., Chen, C.H., Chuang, H.C., Kulp, S.K., Teng, C.M., Chen, C.S., Novel mechanism by which histone deacetylase inhibitors facilitate topoisomerase IIalpha degradation in hepatocellular carcinoma cells. Hepatology 53:1 (2011), 148–159.
62. Di Fazio, P., Lingelbach, S., Schobert, R., Biersack, B., 4,5-Diaryl imidazoles with hydroxamic acid appendages as anti-hepatoma agents. Invest. N. Drugs 33:1 (2015), 104–108.
63. Srinivas, C., Swathi, V., Priyanka, C., Anjana Devi, T., Subba Reddy, B.V., Janaki Ramaiah, M., Bhadra, U., Bhadra, M.P., Novel SAHA analogues inhibit HDACs, induce apoptosis and modulate the expression of microRNAs in hepatocellular carcinoma. Apoptosis 21:11 (2016), 1249–1264.
64. Jiang, W., Guo, Q., Wu, J., Guo, B., Wang, Y., Zhao, S., Lou, H., Yu, X., Mei, X., Wu, C., Qiao, S., Wu, Y., Dual effects of sodium butyrate on hepatocellular carcinoma cells. Mol. Biol. Rep. 39:5 (2012), 6235–6242.
65. Wakabayashi, K., Saito, H., Kaneko, F., Nakamoto, N., Tada, S., Hibi, T., Gene expression associated with the decrease in malignant phenotype of human liver cancer cells following stimulation with a histone deacetylase inhibitor. Int. J. Oncol. 26:1 (2005), 233–239.
66. Ma, B.B., Sung, F., Tao, Q., Poon, F.F., Lui, V.W., Yeo, W., Chan, S.L., Chan, A.T., The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines. Invest. N. Drugs 28:2 (2010), 107–114.
67. Sun, W.J., Huang, H., He, B., Hu, D.H., Li, P.H., Yu, Y.J., Zhou, X.H., Lv, Z., Zhou, L., Hu, T.Y., Yao, Z.C., Lu, M.D., Shen, X., Zheng, Z.Q., Romidepsin induces G2/M phase arrest via Erk/cdc25C/cdc2/cyclinB pathway and apoptosis induction through JNK/c-Jun/caspase3 pathway in hepatocellular carcinoma cells. Biochem. Pharmacol. 127 (2017), 90–100.
68. Chen, M.C., Huang, H.H., Lai, C.Y., Lin, Y.J., Liou, J.P., Lai, M.J., Li, Y.H., Teng, C.M., Yang, C.R., Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma. Oncotarget 7:1 (2016), 402–417.
69. Lu, Y.S., Kashida, Y., Kulp, S.K., Wang, Y.C., Wang, D., Hung, J.H., Tang, M., Lin, Z.Z., Chen, T.J., Cheng, A.L., Chen, C.S., Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. Hepatology 46:4 (2007), 1119–1130.
70. Coradini, D., Zorzet, S., Rossin, R., Scarlata, I., Pellizzaro, C., Turrin, C., Bello, M., Cantoni, S., Speranza, A., Sava, G., Mazzi, U., Perbellini, A., Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But. Clin. Canc. Res. 10:14 (2004), 4822–4830.
71. Ocker, M., Alajati, A., Ganslmayer, M., Zopf, S., Luders, M., Neureiter, D., Hahn, E.G., Schuppan, D., Herold, C., The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. J. Canc. Res. Clin. Oncol. 131:6 (2005), 385–394.
72. Li, X., Zhu, Y., He, H., Lou, L., Ye, W., Chen, Y., Wang, J., Synergistically killing activity of aspirin and histone deacetylase inhibitor valproic acid (VPA) on hepatocellular cancer cells. Biochem. Biophys. Res. Commun. 436:2 (2013), 259–264.
73. Yang, H., Zhan, Q., Wan, Y.J., Enrichment of Nur77 mediated by retinoic acid receptor beta leads to apoptosis of human hepatocellular carcinoma cells induced by fenretinide and histone deacetylase inhibitors. Hepatology 53:3 (2011), 865–874.
74. Ruf, B., Berchtold, S., Venturelli, S., Burkard, M., Smirnow, I., Prenzel, T., Henning, S.W., Lauer, U.M., Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma. Mol Ther Oncolytics, 2, 2015 15019.
75. Lu, Y.S., Chou, C.H., Tzen, K.Y., Gao, M., Cheng, A.L., Kulp, S.K., Cheng, J.C., Radiosensitizing effect of a phenylbutyrate-derived histone deacetylase inhibitor in hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 83:2 (2012), e181–e189.
76. Yuan, H., Li, A.J., Ma, S.L., Cui, L.J., Wu, B., Yin, L., Wu, M.C., Inhibition of autophagy signi fi cantly enhances combination therapy with sorafenib and HDAC inhibitors for human hepatoma cells. World J. Gastroenterol. 20:17 (2014), 4953–4962.
77. Hsu, F.T., Liu, Y.C., Chiang, I.T., Liu, R.S., Wang, H.E., Lin, W.J., Hwang, J.J., Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-kappaB signaling. Int. J. Oncol. 45:1 (2014), 177–188.
78. Lachenmayer, A., Toffanin, S., Cabellos, L., Alsinet, C., Hoshida, Y., Villanueva, A., Minguez, B., Tsai, H.W., Ward, S.C., Thung, S., Friedman, S.L., Llovet, J.M., Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J. Hepatol. 56:6 (2012), 1343–1350.
79. Chen, C.H., Chen, M.C., Wang, J.C., Tsai, A.C., Chen, C.S., Liou, J.P., Pan, S.L., Teng, C.M., Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo. Clin. Canc. Res. 20:5 (2014), 1274–1287.
80. Hamed, H.A., Yamaguchi, Y., Fisher, P.B., Grant, S., Dent, P., Sorafenib and HDAC inhibitors synergize with TRAIL to kill tumor cells. J. Cell. Physiol. 228:10 (2013), 1996–2005.
81. Zhang, J.X., Li, D.Q., He, A.R., Motwani, M., Vasiliou, V., Eswaran, J., Mishra, L., Kumar, R., Synergistic inhibition of hepatocellular carcinoma growth by cotargeting chromatin modifying enzymes and poly (ADP-ribose) polymerases. Hepatology 55:6 (2012), 1840–1851.
82. Nio, K., Yamashita, T., Okada, H., Kondo, M., Hayashi, T., Hara, Y., Nomura, Y., Zeng, S.S., Yoshida, M., Hayashi, T., Sunagozaka, H., Oishi, N., Honda, M., Kaneko, S., Defeating EpCAM(+) liver cancer stem cells by targeting chromatin remodeling enzyme CHD4 in human hepatocellular carcinoma. J. Hepatol. 63:5 (2015), 1164–1172.
83. Spratlin, J.L., Pitts, T.M., Kulikowski, G.N., Morelli, M.P., Tentler, J.J., Serkova, N.J., Eckhardt, S.G., Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines. Anticancer Res. 31:4 (2011), 1093–1103.
84. Shao, H., Gao, C., Tang, H., Zhang, H., Roberts, L.R., Hylander, B.L., Repasky, E.A., Ma, W.W., Qiu, J., Adjei, A.A., Dy, G.K., Yu, C., Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo. J. Hepatol. 56:1 (2012), 176–183.
85. Bitzer, M., Horger, M., Giannini, E.G., Ganten, T.M., Worns, M.A., Siveke, J.T., Dollinger, M.M., Gerken, G., Scheulen, M.E., Wege, H., Zagonel, V., Cillo, U., Trevisani, F., Santoro, A., Montesarchio, V., Malek, N.P., Holzapfel, J., Herz, T., Ammendola, A.S., Pegoraro, S., Hauns, B., Mais, A., Lauer, U.M., Henning, S.W., Hentsch, B., Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - the SHELTER study. J. Hepatol. 65:2 (2016), 280–288.
86. Yeo, W., Chung, H.C., Chan, S.L., Wang, L.Z., Lim, R., Picus, J., Boyer, M., Mo, F.K., Koh, J., Rha, S.Y., Hui, E.P., Jeung, H.C., Roh, J.K., Yu, S.C., To, K.F., Tao, Q., Ma, B.B., Chan, A.W., Tong, J.H., Erlichman, C., Chan, A.T., Goh, B.C., Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. J. Clin. Oncol. 30:27 (2012), 3361–3367.
87. Gruber, W., Peer, E., Elmer, D.P., Sternberg, C., Tesanovic, S., Del Burgo, P., Coni, S., Canettieri, G., Neureiter, D., Bartz, R., Kohlhof, H., Vitt, D., Aberger, F., Targeting class I histone deacetylases by the novel small molecule inhibitor 4SC-202 blocks oncogenic hedgehog-GLI signaling and overcomes smoothened inhibitor resistance. Int. J. Canc. 142:5 (2018), 968–975.
88. Aspeslagh, S., Morel, D., Soria, J.C., Postel-Vinay, S., Epigenetic modifiers as new immunomodulatory therapies in solid tumours. Ann. Oncol. 29:4 (2018), 812–824.
89. Papeleu, P., Vanhaecke, T., Elaut, G., Vinken, M., Henkens, T., Snykers, S., Rogiers, V., Differential effects of histone deacetylase inhibitors in tumor and normal cells-what is the toxicological relevance?. Crit. Rev. Toxicol. 35:4 (2005), 363–378.
90. Falkenberg, K.J., Johnstone, R.W., Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat. Rev. Drug Discov. 13:9 (2014), 673–691.
91. Dawson, M.A., Kouzarides, T., Cancer epigenetics: from mechanism to therapy. Cell 150:1 (2012), 12–27.
92. Wong, J.C., Tang, G., Wu, X., Liang, C., Zhang, Z., Guo, L., Peng, Z., Zhang, W., Lin, X., Wang, Z., Mei, J., Chen, J., Pan, S., Zhang, N., Liu, Y., Zhou, M., Feng, L., Zhao, W., Li, S., Zhang, C., Zhang, M., Rong, Y., Jin, T.G., Zhang, X., Ren, S., Ji, Y., Zhao, R., She, J., Ren, Y., Xu, C., Chen, D., Cai, J., Shan, S., Pan, D., Ning, Z., Lu, X., Chen, T., He, Y., Chen, L., Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response. J. Med. Chem. 55:20 (2012), 8903–8925.
93. Chan, P.C., Wu, C.Y., Chou, L.S., Ho, C.H., Chang, C.W., Chiou, S.H., Lin, W.J., Chen, F.D., Chang, C.A., Hwang, J.J., Liu, R.S., Wang, H.E., Monitoring tumor response after histone deacetylase inhibitor treatment using 3’-Deoxy-3’-[18F]-fluorothymidine PET. Mol. Imag. Biol. 17:3 (2015), 394–402.